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O-119 Oral The value of follicular fluid G-CSF as a biomarker of
embryo implantation potential in monofollicular IVF cycle
A. Osipova1, M.P. Piccinni2, J. Taieb3, V. Gallot1, L. Lombardelli2, M. Petit-
barat4, R. Fanchin5, G. Chaouat4, N. Frydman6, R. Frydman5, N. Le´de´e4
1AP-HP Hoˆpital Antoine Be´cle`re, Service de Gyne´cologie-Obste´trique et
Me´decine de la Reproduction, Clamart, France, 2Centre of Excellence for
Research Transfer and High Education DENOTHE of the University of Flor-
ence, Internal Medicine-Immunoallergology Unit, Florence, Italy, 3AP-HP
Hoˆpital Antoine Be´cle`re, Service de Biochimie, Clamart, France, 4INSERM
U782 Univ Paris-Sud, UMR-S0782, Clamart, France, 5AP-HP Hoˆpital Antoine
Be´cle`re INSERM U782 Univ Paris-Sud, Service de Gyne´cologie-Obste´trique et
Me´decine de la Reproduction, Clamart, France, 6AP-HP Hoˆpital Antoine
Be´cle`re INSERM U782 Univ Paris-Sud, Service d’histologie embryologie
cytoge´ne´tique a` orientation en biologie et ge´ne´tique de la reproduction,
Clamart, France
Introduction: Evaluating the implantation potential of an embryo is one of the
major issues in the assisted reproduction technique. New non invasive methods
are recently available. Granulocyte colony-stimulating factor (G-CSF)–a cyto-
kine, belonging to the family of growth factors, detected in follicular fluid (FF)
is being proposed as a biomarker of oocyte competence.
The purpose of the study was to investigate the predictive value of G-CSF
and other cytokines/chemokines found in the FF in regard to implantation of
the embryo and pregnancy outcomes in natural modified IVF cycles. This pro-
tocol presents a unique monofollicular research model.
Materials and Methods: Retrospective study was performed in Antoine
Be´cle`re hospital. Inclusion criteria for natural modified cycle were: previous
implantation failure in conventional ovarian hyperstimulated IVF/ICSI cycles
or a low ovarian reserve below 38 years old. We obtained FF from 100
cycles, from 83 patients. For this study we selected FF, belonging to the first
attempts of the patients. These 83 cycles led to 54 embryo transfers (ET), result-
ing in 19 deliveries and 6 first trimester miscarriages. According to embryo
morphology 36 high-quality and 18 low-quality embryos were observed. In
10 cycles no oocyte was collected, in 19 no embryo was obtained. Each
sample of FF was blindly tested for their cytokine contents by multiplexed
microsphere-based immunoassays able to simultaneously measure multiple
analytes. Flow cytometric resolution of spectrally distinct microspheres
coupled with capture molecules and reporter fluorochromes bound to detect
antibodies. IL-1a, IL-1Ra, IL-2, IL-4, IL-5, IL-6, IL-8, IL-9, IL-10, IL-12,
IL-13, IL-15, IL-17, IFN-a, TNF-a, G-CSF, GM-CSF, VEGF, PDGF, FGF,
IP-10, MCP-1, CCL5, eotaxin, MIP-1-a and MIP-1-b were analyzed (Bio-
Rad Laboratories, Hercules, CA, USA). In this part of the study G-CSF was
assessed as a potential biomarker using the Area under the ROC (AUrocC)
curve methodology. Thresholds for Anova analysis according to G-CSF
ranges were extrapolated from ROC curves.
Results: AUrocC for FF-GCSF as a biomarker of delivery/ puncture and deliv-
ery/transfer were respectively both at 0.78 and 0.80 (p ¼ 0.0001). AUrocC for
FF-GCSF as a biomarker of clinical pregnancy/puncture and transfer were
respectively at 0.72 and 0.73 (p ¼ 0.0008). FF G-CSF was lower than
8.74 pg/ml in 24 samples (14 transferred), from 8.74 to 12.1 pg/ml in 14
samples (7 transferred), and over 12.1 pg/ml in 45 samples (33 transferred)
and defined low-medium and high G-CSF ranged groups. Clinical pregnancy
rates/puncture and transfer were respectively 12.5%–28%–40% and 14%–
43%–54% in low-medium and high G-CSF ranged groups (p ¼ 0.03 and
0.06). Delivery rates/puncture and transfer were respectively 0%–14%–37%
and 0%–28%–51% in low-medium-and high G-CSF ranged groups (p ¼
0.002 and 0.001). There was no correlation between FF G-CSF levels and
embryo morphology. FF G-CSF levels were significantly lower in no ET com-
pared to ET group (p , 0.05).
Conclusion: FF G-CSF appears to be a non invasive biomarker of oocyte com-
petence in natural controlled cycle.
Our data confirms previous publications and suggests that non invasive
immunological analysis of oocyte competence will allow to choose which
embryo can be transferred independently from morphology assessment.
With the development of routine immunological diagnostic technique use of
new non invasive powerful biomarkers of oocyte competence and embryo
implantation will modify our clinical practice in the next future.
The study was supported by the European network of excellence EMBIC
(contract 512040).
O-120 Oral Viability assesment of cryopreserved embryos by near
infrared spectroscopy: preliminary results
C.G. Vergouw1, L.L. Botros2, K. Judge2, M. Henson2, P. Roos2, R. Schats1,
P.G.A. Hompes1, C.B. Lambalk1
1VU University Medical Center, Reproductive Medicine, Amsterdam, The
Netherlands, 2Molecular Biometrics LLC, Research, Chester New Jersey, U.S.A.
Introduction: Cryopreservation of supernumerous, good quality embryos is
routinely offered in IVF/ICSI programs. The number of frozen-thawed cycles
and its contribution to overall pregnancy results has increased over the last
few years, mainly because of an increase in applying Single Embryo Transfer
(SET) in the fresh cycle. SET is even often performed when cryo-thawed
embryos are transferred. The quality of an embryo has a great influence on
pregnancy outcomes, so the selection of the embryo with the best implantation
potential is important. New parameters to predict embryo viability, like non-
invasive metabolomic profiling, have been studied. Metabolomics is the
study of small-molecule metabolite byproducts left behind from cellular pro-
cesses. By measuring byproducts of the embryonic metabolism you get a snap-
shot of the physiology of an embryo which translates to viability. Recently,
several studies showed that metabolomic profiling of biomarkers of metabolism
by Near Infrared (NIR) spectroscopy correlated with ongoing pregnancy in
fresh IVF/ICSI cycles, when the transferred embryos were selected by conven-
tional selection criteria. In this study, we investigated if metabolomic profiling
of biomarkers of metabolism by NIR spectroscopy correlated with ongoing
pregnancy after SET of frozen-thawed embryos.
Material & Methods: Between January and April 2008, embryos of 52
patients scheduled for a frozen-thawed SET were included. Day 4 embryos
were thawed using a standard slow protocol and then cultured for 20–24
hours prior to transfer. The embryos were cultured individually overnight in
25 ml pre-equilibrated medium drops. Alongside, embryo-free media drops
were incubated as controls. Embryos were selected for transfer by routine mor-
phological criteria. After transfer, the medium drop in which the transferred
embryo was cultured and a control medium drop were immediately frozen
(21968C). Individual metabolomic profiles were obtained from 10 ml media
samples using NIR spectroscopy (Molecular Biometrics Inc.). Cryopreserved
embryo viability scores were calculated from a logistic regression of genetic
algorithm selected NIR spectral regions, and leave-one-out cross validation.
The metabolomics data were compared to pregnancy outcomes.
Results: Of the 52 cryopreserved SET 9 (17.3%) ongoing pregnancies were
established as detected by fetal cardiac activity (FCA) 12 weeks post embryo
transfer. Viability scores calculated from four distinct NIR spectral regions sig-
nificantly discriminated (P ¼ 0.007) between cryopreserved embryos that
established ongoing pregnancies (FCA positive, 0.33+0.12) compared to
those that failed to implant (FCA negative, 0.16+0.27). A partial least
squares discriminatory analysis model was also developed to discriminate
between the FCA positive and negative samples and was able to successfully
distinguish 11 of 19 (58%) positive and 37 of 44 (84.1%) negative at 90% con-
fidence limits for each group.
Conclusion: The results indicate that NIR spectral analysis of post-thaw
samples may allow discrimination of viable and non-viable cryopreserved
embryos. Coupled with a pre-freeze analysis this may allow stronger predict-
ability for frozen SETs. The data awaits confirmation in a blinded study.
SELECTED ORAL COMMUNICATION SESSION
Session 32: Ethics and law
Tuesday 30 June 2009 10:00–11:30
O-121 Oral Retrospective study of U.S. egg donors: risks,informed
consent, anonymity, satisfaction, & need for long-term follow-up: results &
recommendations
J.P. Schneider1, W. Kramer2
1Arizona Community Physicians, Medicine, Tucson AZ, U.S.A., 2Donor Sibling
Registry, Registry, Nederlands CO, U.S.A.
Introduction: Success in U.S. IVF clinics is measured by the likelihood of live
births. Less attention is paid to the outcomes and health of egg donors or the
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future concerns of donor-conceived children. After egg retrieval, donors are
discharged from the IVF clinic but are rarely contacted afterwards. Long-
term medical risks to egg donors have never been systematically studied.
Only a few published studies have considered the emotional and psychological
effects of egg donation on donors. Potential egg donors sign informed-consent
forms without actually receiving information on long-term risks, because such
risks are not known.
Methods: This study presents findings from a large sample of egg donors, up to
22 years after egg donation; 155 of them completed a survey on the website of
Donor Sibling Registry (DSR), a US-based registry that helps donor-conceived
people make mutual-consent contact with their half siblings and/or donors. An
online survey asked about medical complications and subsequent health pro-
blems, contact with IVF clinic, donors’ satisfaction with the donation
process, and current feelings.
Results were based on 155 women , 1 to 22 years (mean, 9.4þ25.2 years)
past their first donation, which occurred at a mean age of 26.4. Reported
medical complications included 32.6% with some degree of OHSS and 4.9%
with subsequent infertility. Only 2.6% had been contacted by the IVF clinic
for medical updates; 34.2% reported medical changes they thought would be
of interest to donor children and half had attempted to report these changes
to the clinic, with variable results. Many of those who did not report didn’t
realize they could or should. Almost all were open to contact with recipient
families (but this finding of course reflects selection bias in the sample). A
common theme was desire to know the outcome of the egg donation. Donors
frequently had not sought information because they were confused about the
definition of “anonymity” or “confidentiality,” believing that anonymity
meant they were not to contact the clinic and/or that the clinic could not
contact the recipients to provide them information.
Conclusions and recommendations: IVF clinics need to give anonymous egg
donors clearer guidelines re asking for outcome information or giving the clinic
medical updates to benefit their biological children. Counseling should also
inform donors that in later years they might feel differently about the egg
donation than at the time of donation. Additional long-term studies are
needed to ascertain egg donors’ risks of infertility or cancer. We recommend
that IVF clinics maintain donor records indefinitely (This will also permit sys-
tematic follow-up of egg donors to finally determine the potential health risks);
develop protocols to contact donors regularly to update medical information on
the donor’s health and information of interest to recipients; educate egg donors
about the importance of contacting the IVF clinic, even years later, to provide
such information; contact recipient families with relevant information provided
by the egg donor; notify donors if any IVF-conceived children are born with
genetic abnormalities; educate egg donors of the possible curiosity of the
child to be born and make egg donors and recipient families aware of resources
for updating and sharing medical information, such as the Donor Sibling
Registry.
O-122 Oral On consent rules for storing embryos
G. Hartshorne1, S. Sheldon2, P. Sozou1
1University of Warwick, Warwick Medical School, Coventry, United Kingdom,
2Kent University, Kent Law School, Canterbury, United Kingdom
Introduction: Couples have embryos frozen in order to gain the option of
transferring them in future, with the aim of creating a pregnancy and ultimately
a live birth. Problems can arise when couples separate. Under UK law, embryos
cannot be transferred without the current consent of both genetic parents. The
issue came to public prominence in the case of Natallie Evans, who lost the
opportunity to have her own genetic children after her relationship ended and
her partner withdrew consent for embryo storage. This study examines the
case for a change in consent laws to give couples a choice of consent
agreements.
Materials & methods: A possible change in the law, to give couples a choice
of two types of consent agreement, is considered. One type of agreement would
be in line with current consent procedures, allowing either genetic parent to
withdraw consent up to embryo transfer. The other type of agreement would
involve one member of the couple signing away the right to withdraw
consent, so that their partner would have control over the embryo. The
couple would then decide between themselves which type of consent agree-
ment to sign. The benefits of and possible objections to this change in the
law are analysed according to philosophical and legal principles.
Results: The proposed change in the law may directly benefit both members of a
couple in a situation where they would not create frozen embryos together under
the current law but would do so under the proposed new law. For example, a
woman in the position of losing her fertility to urgent medical treatment may
be unwilling to have embryos created with her partner and frozen if the man
retains the right to withdraw consent at a later date. It is then in the man’s inter-
ests to be able to sign away the right to later withdraw consent. More generally,
the change gives couples more autonomy by allowing them a choice, and does
not remove any option currently open to them. Possible objections to this
change in the law take three main forms: (i) concern about the welfare of a
child born to parents who have separated; (ii) concern about any broader costs
to society from the birth of such children; and (iii) concern that a genetic
parent who signed away his or her right to withdraw consent would be the
victim of an unfair contract. It is shown that the first objection would imply
that a baby born to parents not together has a life not worth living; this seems
absurd and also conflicts with the general principle under English law that
‘wrongful life’ is not recognised. Both (i) and (ii) conflict with the legality and
practice of offering fertility treatment to single women, and the removal of the
‘need for a father’ in the UK Human Fertilisation and Embryology Act 2008.
For (iii), it is generally accepted that a necessary condition for a contract to be
unfair contract is that the wronged person is either likely to be in an unfit state
of mind or has insufficient information at the time of signing the contract.
Thorough counselling, with mandatory individual counselling for both partners,
may answer possible concerns about unfair contracts.
Some practical considerations remain, such as the time periods over which
embryos can be used under different consent agreements.
Conclusion: There is a strong case for revising the law to allow couples a
choice of consent agreements when they opt to have embryos frozen. Robust
consent-advisory procedures will be needed, helping couples to think through
their consent decisions more thoroughly than at present.
O-123 Oral Avoiding transgenerational health risks: a morally
acceptable reason for sex selection?
A.L. Bredenoord1, W. Dondorp1, G. Pennings2, G. De Wert1
1Maastricht University, Health Ethics & Society / Research Institute GROW,
Maastricht, The Netherlands, 2Ghent University, Bioethics Institute Ghent,
Ghent, Belgium
Introduction: Mitochondrial DNA (mtDNA) mutations are an important cause
of severe diseases. As there is no curative treatment, helping carriers to have
healthy children has been a central focus of attention. New techniques aimed
at achieving this are preimplantation genetic diagnosis (PGD) and possibly in
the future nuclear transfer (NT). However, when applying PGD for mtDNA dis-
orders, it is conceivable that only affected embryos are available for transfer.
Moreover, in a clinical application of NT it will be difficult to avoid small
amounts of affected mitochondria to come along with the oocyte, pronuclei
or nucleus of the recipient woman.
Although neither PGD nor NT can ‘guarantee’ a mutant free child, the
mutant load of the resulting child is expected to be (far) below the threshold
to disease expression. Nevertheless, due to the existence of a genetic bottle-
neck, the mutant load may rise again in the third generation - the couple’s
grandchildren. As mitochondria are transferred maternally, male offspring
will not pass on their mutant DNA to the next generation. This leads to the
question whether the avoidance of transgenerational risks provides a morally
acceptable reason for sex selection.
Material & methods: Literature review; ethical analysis.
Results: We do not consider the possible occurrence of transgenerational
health risks to be a contra-indication for PGD and NT. After all, it is far
from certain that the genetic bottleneck will lead to a higher mutant load in a
possible third generation. Nor is it certain that female offspring will reproduce
and if she does, she may resort to PGD or NT herself. However, both these risks
and the burden of difficult reproductive decisions are important enough to be
prevented if reasonably possible. Theoretically, this can be achieved by creat-
ing or transferring only male embryos.
Whereas sex selection is highly controversial for nonmedical use, it is gen-
erally accepted to avoid the birth of a child with a severe X-linked genetic dis-
order. In our case, sex selection would be used to avoid health effects further
along the line of generations. Would that be acceptable? A similar question
has arisen in PGD for X-linked diseases, where sex selection against healthy
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carrier embryos has the same purpose. Because these applications of sex selec-
tion are still done for reasons of health, they should not give rise to the moral
concerns associated with sex selection for nonmedical reasons.
Ideally, sex selection would be an integrated part of PGD for mtDNA
mutations, which may perhaps also be done as a possible confirmatory step
after NT. Information about the sex would then be obtained as a by-product
of PGD performed for other reasons, or sex identification is added to PGD.
Given the limited nature of the risk to be avoided, the proportionality of this
extra element must be carefully observed. This allows to preferentially transfer
male embryos, but only as a secondary criterion and not as a reason to conduct a
new cycle. PGD solely to avoid a transgenerational risk would not be accepta-
ble either from this point of view. Preconceptional sex selection (sperm separ-
ation) could be considered to increase the number of male embryos available
for transfer. However, since these methods are not fail-safe, sexing of the
embryos afterwards would still be needed if one wants certainty. Unfortunately,
the most promising technique (flow cytometry) is not completely established
yet. High costs would also affect the proportionality, given the limited nature
of risks to be avoided.
Conclusion: Notwithstanding the theoretical acceptability of sex selection to
avoid transgenerational health risks, the proportionality of this application in
the context of mtDNA mutations depends on various factors and needs
further scrutiny.
O-124 Oral Access to genetic and biographical history in donor-
conception: an analysis of provisions permitting disclosure of donor
identity
E. Blyth1, L. Frith2
1University of Huddersfield, School of Human and Health Sciences, Hudders-
field, United Kingdom, 2University of Liverpool, School of Population Com-
munity & Behavioural Sciences, Liverpool, United Kingdom
Introduction: Traditionally, gamete donation has been practiced so that donors
and recipients are unknown to each other and individuals conceived following a
donor procedure receive little or no information about their donor. However, a
key topic of recent debate, policy formulation and regulation has been the
extent to which donor-conceived people should be allowed to ascertain infor-
mation about their genetic and biographical history. Worldwide, ten jurisdic-
tions currently enable donor-conceived individuals to learn the identity of
their donor and an eleventh has passed legislation enabling them to do so
that is yet to be implemented.
Material and Methods: The presentation is based primarily on a review and
analysis of legislation and policy documentation in the eleven jurisdictions
that have either already implemented legislation enabling donor-conceived
individuals to learn the identity of their donor (10) or have yet to implement
such legislation that has been approved by the relevant legislature (1). Where
such information is not readily available in print, this has been obtained directly
from relevant authorities in each jurisdiction.
Results: The analysis provides details of the legislation that has been passed
and presents data on the following areas: (1) safeguards to the interests of
donors and the promotion of donors’ rights; (2) limits placed on the number
of offspring or families per donor; (3) arrangements for managing a formal reg-
ister of donor procedures; (4) the age at which a donor-conceived person can
obtain information and any provisions for earlier access to information and/
or access to information by the parent of a donor-conceived child acting on
behalf of their son or daughter; (5) access to donor information by the descen-
dant of a donor-conceived person; (6) restriction on the provision of infor-
mation; (7) provisions for access to information in respect of a donor
procedure undertaken before the implementation of legislation permitting dis-
closure of donor identity, and (8) provisions enabling a donor-conceived person
to ascertain information about any other individual who shares the same donor.
Conclusions: The presentation will conclude by identifying a range of
measures that may be taken to promote the ability of donor-conceived people
to learn about their genetic and biographical history.
O-125 Oral Who should pay for assisted reproductive techniques? -
answers from patients, professionals, and the general public in Germany
O. Rauprich1, E. Berns1, J. Vollmann1
1Institute for Medical Ethics and History of Medicine, Ruhr-University
Bochum, Bochum, Germany
Introduction: In 2004, new legal regulations have been introduced in
Germany, restricting the coverage of statutory health insurances to 50% of
the costs for ART procedures and medication. As a result, the amount of per-
formed treatment cycles as well as the amount of children born after IVF/
ICSI declined by about one third. Against this background, we conducted a
survey among patients, professionals, and the general public in Germany on
their opinions regarding financing ART.
Material and Methods: The views of German patients (n¼ 1598, response rate
RR ¼ n.d.), reproductive physicians (n¼ 230, RR ¼ 36%), psychosocial coun-
sellors (n ¼ 66, RR ¼ 67%), medical ethicists (n¼ 135, RR¼ 55%), social
lawyers (n ¼ 140, RR ¼ 45%), health politicians (n¼ 78, RR¼ 27%), and the
general public (n ¼ 1005, RR¼ n.d.) regarding costs, cost-efficiency, savings
potential, funding, co-payment, and special financing plans (egg-sharing,
money-back-guarantee) of ART have been surveyed using standard question-
naire techniques (Paper and Pencil Interviewing PAPI, Computer Aided Web
Interviewing CAWI, Computer Aided Telephone Interviewing CATI).
Results: In all groups, the vast majority supported coverage of ART by statu-
tory health insurances and/or tax money. At the same time, about 1/3 of the
patients, 2/3 of the physicians and 3/4 of all other groups considered co-pay-
ments of patients as appropriate. The median amount of co-payment considered
appropriate ranged between 15–25% of the costs, considerable less than what
patients in Germany actually have to pay (50%). Regression analyses showed
that the support for public coverage of ART was strongly correlated with the
views (i) of infertility as an illness, (ii) that there is a need for assisted repro-
duction for infertile couples with an unfulfilled desire for children, and (iii)
that every human should have the opportunity to have children.
To increase the health insurance premium by 1.50 Euros per month in order
to cover ART was rejected by a relative majority of psychosocial counsellors,
medical ethicists, and health politicians, but supported by most respondents of
the other groups. To reduce services in other areas of health care in favour for
reproductive medicine was supported by the group of reproductive physicians
only. They saw some potential for savings with regard to the medication, but
not with regard to diagnostics, laboratory techniques, and anaesthesia.
Among the patients and physicians, about the same number of respondents
was in favour for and opposed to the possibility for women to receive a discount
on infertility treatment by sharing their eggs with other couples. All other
groups rejected such a commercial egg-donation with a majority of two
third. A money-back-guarantee in case of unsuccessful treatments was unani-
mously objected by all groups, including patients.
Conclusions: Policy makers should take notice of the opinions of patients, pro-
fessionals and the general public in Germany regarding financing ART. The
data show a significant tendency in favour of reduced co-payments and
increased health insurance coverage. Potential for significant savings were
neither seen in the field of assisted reproduction nor in other areas of health
care. Introducing elements of commodification and market mechanisms in
reproductive medicine was rejected.
The majoritarian approval of covering ART was founded on the beliefs that
couples suffering from involuntary childlessness are in need for treatment
because infertility is a condition of ill health and having children is a basic
opportunity everyone should have. A rational and normative assessment of
the respondents’ opinions on financing ART should deal with these founda-
tional beliefs.
O-126 Oral Cross-border fertility care: a survey of Canadian and
American clinics, assessing scope of practice and communication between
patients and caregivers
E.G. Hughes1, D. DeJean2
1McMaster University, Department of OB/GYN, Hamilton Ontario, Canada,
2McMaster University, Department of Epidemiology and Statistics, Hamilton
Ontario, Canada
Introduction: Patients seek cross-border fertility care for many reasons. This
practice challenges the continuity, quality and ethics of care. In order to
better understand these issues, a survey of Canadian and American fertility
clinics was undertaken. Its objectives were to: 1) identify the scope and
volume of cross-border services in North America and 2) evaluate communi-
cation between patients and their caregivers.
Materials and Methods: Each survey was developed with input from clini-
cians, nurses and patients. Surveys were pre-tested in four different centers
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for time and ease of use, ambiguity and comprehension. Between October 1st
and November 30th 2008, the survey was mailed twice to 26 Canadian fertility
clinics and to 8 individual Canadian MDs, satelliting with these clinics. A
modified survey was distributed online, to 392 American SART-member
clinics. Results were tabulated and summarized using SPSS.
Results: 28 Canadian and 125 American surveys were completed (78% and
32% response rates). For Canada, the largest proportion of surveys (50%)
was from Ontario. Respondents reported offering a total of 6927 stimulated
IVF cycles per year, equivalent to 77% of the total cycles provided in
Canada for 2007 (n ¼ 9019). The most common out-of-country treatment
sought by Canadians was IVF with anonymous donor-eggs: 363 of 452 patients
treated (80%). Canadian respondents provided satellite monitoring for 431
women undergoing out-of-country IVF. For patients entering Canada in
order to receive fertility treatment (n ¼ 146), the largest demand was for IVF
(73% of patients treated). 52% of respondents recommended specific destina-
tion countries to their patients, but not specific providers. Confidence in
safety, effectiveness and ethicality were considered very important by 71–
80% of respondents. Respondents felt that patients were most concerned
with effectiveness (88%) and safety (80%). 88% of Canadian respondents
always provide the information requested by the destination clinic. Canadian
clinics were most interested in receiving information about complications of
treatment, number of embryos transferred and frozen.
For the United States survey, the largest proportion of responses came from
the Southern US (31%). Respondents reported offering 35,387 stimulated IVF
cycles per year, equivalent to 41% of the total 85,326 stimulated cycles
reported to SART for 2006. Responding US clinics reported treating 927
out-of-country patients, 51% of them with standard IVF. 36% of incoming
patients were from Latin America and 23% from Europe. The largest pro-
portion of the 220 patients leaving the US in order to receive IVF or donor
egg IVF, traveled to India / Asia: 41% and 52% respectively. Respondents
reported that confidence in treatment effectiveness and safety, as well as infor-
mation from other patients, were very important factors in patients’ decisions to
come to their clinics. The majority of respondents felt that recent laboratory
results and track sheets from previous cycles should always be sent with out-
of-country patients. Good concurrence was seen between Canadian and Amer-
ican clinics’ ratings of key data that should be provided along with returning
patients.
Conclusions: The number of Canadians traveling to the United States for ART
is equivalent to approximately 5% of the total cycles performed in Canada.
Eighty percent of these women seek anonymous donor egg IVF. Less than
1% of US patients leave the country for fertility care and for them, the most
popular destination is India / Asia, for standard or donor egg IVF. In the
USA, approximately 3% of the total ART volume is made up of women
coming into the country for care. US clinicians stress the need for recent lab
data and previous stimulation track sheets. All parties surveyed rated effective-
ness and safety of care as paramount in patient choice of destination.
This research was supported by Assisted Human Reproduction Canada
SELECTED ORAL COMMUNICATION SESSION
Session 33: Preimplantation genetic diagnosis
Tuesday 30 June 2009 10:00–11:30
O-127 Oral PCR-based detection of chromosomal unbalances on
embryos: a possible future (r)evolution of PGD for chromosomal
translocations
F. Fiorentino1, G. Kokkali2, A. Biricik1, B. Ismiailoglu1, R. De Palma1, D.
Stavrou2, A. Nuccitelli1, L. Arizzi1, M. Baldi1, K. Pantos2
1GENOMA, Molecular Genetics Laboratory, Rome, Italy, 2Genesis Athens
Hospital, Centre for Human Reproduction, Athens, Greece
Introduction: Preimplantation genetic diagnosis (PGD) has been offered to
carriers of balanced translocations as an alternative to prenatal diagnosis. Flu-
orescence in-situ hybridisation (FISH) is the method of choice for detecting
chromosome rearrangements. The FISH strategy involves the simultaneous
use of telomeric probes in combination with centromeric probes (reciprocal
translocations), or alpha-satellite/locus-specific enumerator probes (Robertso-
nian translocations).
Here we present the development of a polymerase chain reaction (PCR)-
based PGD approach for detection of chromosomal imbalances on embryos
derived from both reciprocal and Robertsonian translocation carriers. The pro-
cedure involves testing of single blastomeres by fluorescent multiplex PCR
analysis of polymorphic short tandem repeat (STR) markers located along
the chromosomes involved by translocation.
Material & methods: STRmarkers were selected to be located at either side of
each breakpoint (reciprocal translocations) or at any point of the chromosomes
involved (Robertsonian translocation). STR markers were also included to
determine the copy number of chromosomes 13, 14, 15, 16, 18, 21, 22, X, Y
in patients of advanced maternal age. Informativity testing of STR markers
was performed for both partners of each couple. Only fully informative
markers presenting alleles not shared by the partners were selected. In order
to avoid misdiagnosis due to possible allele drop-out (ADO) occurrences, at
least three STR for each chromosome were included in the protocol.
Embryos were diagnosed as “normal-balanced” if PCR results indicated two
signals (peaks) for each chromosome tested. Embryos were diagnosed as
“unbalanced” if the PCR results showed a deviation from the “normal-
balanced” signal pattern, such as trisomies (three peaks), monosomies (one
peak) and nullisomies (no PCR signals).
Results: Twelve PGD cycles were carried out for 12 couples carrying six
different reciprocal translocations and two Robertsonian translocations. The
mean maternal age was 36.4+4.6 years. A total of 204 oocytes were collected,
158 (77.5%) were MII, 126 (79.7%) fertilized and 110 embryos were biopsied
on day 3. PCR was successful in 102/110 (92.7%) blastomeres, accounting a
positive amplification on a total of 1048/1128 (92.9%) loci. Overall, 102
(92.7%) embryos were successfully diagnosed, 52 of which resulted normal/
balanced, 44 were unbalanced and 6 resulted to be haploid. PGS was included
in the PGD protocol of five couples, involving testing of 45 embryos, 40
(88.9%) of which were successful diagnosed and 24 (60.0%) showed aneuploi-
dies. Embryos suitable for transfer where identified in 10 cycles. Following
transfer of 23 embryos (mean 1.9+1.1), 7 women had a clinical pregnancy
confirmed with fetal sacs and heart beat (70.0% pregnancy rate per embryo
transfer). A total of 13 embryos implanted (56.5% implantation rate per
embryo transferred), for 10 of which heart beat was also detected. Only 2
couples accepted to undergo to prenatal diagnosis, performed by chorion
villus sampling (CVS) or amniocentesis, which confirmed the PGD results.
All pregnancies are still ongoing.
Conclusions: The above results demonstrate the feasibility and reliability of
our PCR-based PGD protocol for detection of chromosomal imbalances. The
present technique has the potential to overcome to several inherent limitation
of the FISH procedure, such as suboptimal fixation, overlapping signals, split
signals, lack of signals, cross-hybridization, polymorphisms, limited avail-
ability of the probes, combination of colours, decreasing of the accuracy
with re-probing. This approach has the advantage to be rapid, low expensive,
amenable to automation, involving an easy procedure and data interpretation.
Unlike FISH, with the presented protocol is also possible to distinguish the par-
ental origin of chromosomes, allowing detection of uniparental disomies and
the achievement of a DNA fingerprint for each embryo, useful for identification
of embryos that have implanted. Finally, because cell fixation is not necessary,
the PCR-based protocol represents an easier procedure for management of
transport PGD. Considering the encouraging preliminary clinical outcome
obtained, this approach has the potential to represent a valuable alternative to
FISH-based PGD.
O-128 Oral IVM with non-elevated E2 levels and PGD for BRCA1
mutation in a breast cancer patient. First report on mutation-free twin’s
pregnancy
D. Meirow1, B. Feldman2, A. Hourvitz1, J. Levron1, M. Brengauz1, K. Dotan2,
J. Dor1
1Sheba Medical Center, IVF unit, Tel Hashomer Ramat Gan, Israel, 2Sheba
Medical Center, Danek Gertner Institute of Human Genetics, Tel Hashomer
Ramat Gan, Israel
Introduction: Young breast cancer patients frequently wish to have biologic
children but reproductive decisions are difficult especially when fertility
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